Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.79
+0.96 (5.70%)
At close: Oct 15, 2026, 4:00 PM EDT
17.85
+0.06 (0.34%)
After-hours: Oct 15, 2026, 7:30 PM EDT
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $401.25M in the quarter ending June 30, 2026, a decrease of -34.34%. This brings the company's revenue in the last twelve months to $1.97B, down -20.44% year-over-year. In the year 2025, Sarepta Therapeutics had annual revenue of $2.20B with 15.58% growth. That makes Sarepta Therapeutics the 4,989th largest company in the world by revenue and 1,303rd in the United States.
Revenue (ttm)
$1.97B
Revenue Growth
-20.44%
P/S Ratio
0.95
Revenue / Employee
$2,364,484
Employees
835
Market Cap
1.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.20B | 296.26M | 15.58% |
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
| Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
| Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
| Dec 31, 2019 | 380.83M | 79.80M | 26.51% |
| Dec 31, 2018 | 301.03M | 146.45M | 94.74% |
| Dec 31, 2017 | 154.58M | 149.16M | 2,751.58% |
| Dec 31, 2016 | 5.42M | 4.17M | 332.64% |
| Dec 31, 2015 | 1.25M | -8.50M | -87.16% |
| Dec 31, 2014 | 9.76M | -4.46M | -31.38% |
| Dec 31, 2013 | 14.22M | -23.11M | -61.91% |
| Dec 31, 2012 | 37.33M | -9.66M | -20.56% |
| Dec 31, 2011 | 46.99M | 17.57M | 59.72% |
| Dec 31, 2010 | 29.42M | 11.84M | 67.30% |
| Dec 31, 2009 | 17.59M | -3.67M | -17.28% |
| Dec 31, 2008 | 21.26M | 10.27M | 93.52% |
| Dec 31, 2007 | 10.99M | 10.87M | 9,428.06% |
| Dec 31, 2006 | 115.29K | -4.67M | -97.59% |
| Dec 31, 2005 | 4.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vir Biotechnology | 303.23M |
| Maravai LifeSciences Holdings | 208.78M |
| UroGen Pharma | 188.73M |
| Mesoblast | 120.25M |
| Xencor | 104.97M |
| Septerna | 98.88M |
| Agios Pharmaceuticals | 98.34M |
| Zymeworks | 37.13M |
SRPT News
- 1 day ago - Sarepta presents new preclinical data at 22nd Meeting of OTS on SRP-1003 - TheFly
- 1 day ago - Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting - Business Wire
- 7 days ago - Sarepta price target lowered to $17 from $19 at RBC Capital - TheFly
- 10 days ago - Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT - Business Wire
- 15 days ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 15 days ago - Sarepta presents new data on ELEVIDYS in DMD at WMS Congress - TheFly
- 15 days ago - Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne - Business Wire
- 15 days ago - Sarepta price target lowered to $20 from $23 at JPMorgan - TheFly